Skip to Content


Treatment for Nausea/Vomiting -- Chemotherapy Induced, Nausea/Vomiting -- Postoperative

GSK Provides Update on Regulatory Filings for Zunrisa/Rezonic

LONDON, Sept. 28, 2009--GlaxoSmithKline (GSK) has made the difficult decision to discontinue the regulatory filings for Zunrisa/Rezonic (casopitant), which was being developed for chemotherapy-induced and post-operative nausea and vomiting. Regulatory applications were filed in a number of countries worldwide and GSK is currently communicating with those authorities and all study investigators.

GSK has made this decision, after regulatory consultation, based on the company’s assessment that significant further safety data would be required to support the registration of casopitant on a worldwide basis, which would take a considerable time to produce. Consequently, all on-going regulatory files for casopitant are being withdrawn.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit





UK Media enquiries:

Philip Thomson

(020) 8047 5502


Claire Brough

(020) 8047 5502


Stephen Rea

(020) 8047 5502


Alexandra Harrison

(020) 8047 5502


Gwenan White

(020) 8047 5502




US Media enquiries:

Nancy Pekarek

(919) 483 2839


Mary Anne Rhyne

(919) 483 2839


Kevin Colgan

(919) 483 2839


Lisa Behrens

(919) 483 2839




European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564


Sally Ferguson

(020) 8047 5543


Gary Davies

(020) 8047 5503




US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419


Jen Hill Baxter

(215) 751 7002


Posted: September 2009

Related Articles

Rezonic (casopitant) FDA Approval History

View comments